The Netherlands X-omics Initiative will have a strong focus on training and outreach.
At this page we will keep you informed about all X-omics news, highlights and relevant publications.
The EnFORCE project (Enabling Functional Omics in Routine Clinical Environments) is a public-private partnership between Radboudumc and Bruker Daltonics co-funded by Health~Holland to develop computational solutions for clinical proteomics, led by X-omics consortium member Hans Wessels, congratulations!
EnFORCE will develop diagnostic workflows for expression proteomics and glycoproteomics using the “PaSER” parallel GPU-computing platform from Bruker. This translational research will provide the foundations for routine implementation of holistic clinical proteomics data in both personalized and large-scale population biomarker applications. EnFORCE will work with patients with congenital disorders of glycosylation or multiple myeloma, aiming at providing less cumbersome, faster and successful diagnostics as well as personalized treatment strategies by better informed decisions.
Every person appears to have a completely unique immune system. The way our immune system responds to pathogens varies from person to person. Researchers at Utrecht University and UMC Utrecht, including our core team member Albert Heck, discovered that each person develops a unique arsenal of antibodies, which are proteins produced as part of the body's immune response to infection. Also, the concentration of these proteins changes in a unique way during illness or after a vaccination.
The team discovered the diversity when they monitored antibodies in the blood of healthy and seriously ill individuals. The researchers analyzed the concentrations of all co-appearing antibodies in the blood. They discovered that there was no overlap whatsoever in this respect between the blood samples of the people investigated. The composition and concentrations of the antibodies were completely different in each person. The concentrations of antibodies also appeared to rise and fall in a unique way during illness. The antibodies themselves also differed. Even antibodies that were aimed to target the exact same pathogens appeared to differ slightly at a molecular level.
Until now, this distinctiveness had not been noticed. The team developed an extremely sensitive analysis that reveals minute differences in mixtures of antibodies. The method is a refinement of mass spectrometry.
The results of this study may help explain why some people are more prone to becoming ill, or why they recover faster from illness than others. Extreme diversity in immune responses could also create new possibilities for personalized treatments and vaccinations. Results have been published in the journal Cell Systems.